ENANTA PHARMACEUTICALS INC (ENTA) Stock Profile — Insider Trades & Financials

Revenue$18.6M

Net Income-$11.9M

EPS$-0.42

Market Cap$399.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Jay Luly

CEO & Executive Director

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The companyâs product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Founded: 1995

⚡

Core Efficiency

ROE?

-9.43%

ROA?

-3.62%

D/E Ratio?

1.60

Op. Margin?

-60.45%

📊

Profitability Ratios

Net Margin?

-64.13%

Loading company sections...

ENANTA PHARMACEUTICALS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness